Glenmark Pharmaceuticals LimitedNSE: GLENMARK

Glenmark Pharmaceuticals Limited Press Release Mar 03 2025

· Issued by Glenmark Pharmaceuticals Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Glenmark Pharmaceuticals Inc., USA has acquired and launched Acetylcysteine Injection in single-dose vials, as reported in the filing. This product is expected to have therapeutic effects similar to an existing drug on the market. The announcement highlights Glenmark's commitment to expanding its injectable portfolio in the U.S. market.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/glenmark-pharmaceuticals-limited-press-release-mar-03-2025

Watch Glenmark Pharmaceuticals' latest callGlenmark Pharmaceuticals (NSE:GLENMARK) Q2 2026 Earnings Call · Replay · Nov 6

Release

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 03, 2025, titled "Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL(200 mg/mL) Single-Dose Vials".

Glenmark Pharmaceuticals Limited on 6ix

Earlier from Glenmark Pharmaceuticals

Later from Glenmark Pharmaceuticals

All Glenmark Pharmaceuticals news releases